<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="6304">
  <stage>Registered</stage>
  <submitdate>25/10/2016</submitdate>
  <approvaldate>25/10/2016</approvaldate>
  <nctid>NCT02949128</nctid>
  <trial_identification>
    <studytitle>Single Arm Study of ALXN1210 in Complement Inhibitor Treatment-Na√Øve Adult and Adolescent Patients With Atypical Hemolytic Uremic Syndrome (aHUS)</studytitle>
    <scientifictitle />
    <utrn />
    <trialacronym />
    <secondaryid>2016-002027-29</secondaryid>
    <secondaryid>ALXN1210-aHUS-311</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Atypical Hemolytic Uremic Syndrome (aHUS)</healthcondition>
    <conditioncode>
      <conditioncode1>Other</conditioncode1>
      <conditioncode2>Research that is not of generic health relevance and not applicable to specific health categories listed above</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Blood </conditioncode1>
      <conditioncode2>Other blood disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Renal and Urogenital</conditioncode1>
      <conditioncode2>Kidney disease</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Renal and Urogenital</conditioncode1>
      <conditioncode2>Other renal and urogenital disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Blood </conditioncode1>
      <conditioncode2>Anaemia</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Other interventions - ALXN1210

Experimental: ALXN1210 - ALXN1210


Other interventions: ALXN1210
Single loading dose on Day 1, followed by regular maintenance dosing beginning on Day 15, based on weight.
= 40 to &lt;60 kg: 2400 mg loading, then 3000 mg every 8 weeks
= 60 to &lt;100 kg: 2700 mg loading, then 3300 mg every 8 weeks
=100 kg: 3000 mg loading, then 3600 mg every 8 weeks

</interventions>
    <comparator />
    <control />
    <interventioncode>Other interventions interventions</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Complete TMA response</outcome>
      <timepoint>26 weeks</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Dialysis requirement status</outcome>
      <timepoint>26 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Time to Complete TMA Response</outcome>
      <timepoint>26 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Complete TMA Response status over time</outcome>
      <timepoint>26 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Observed value and change from baseline in estimated glomerular filtration rate (eGFR)</outcome>
      <timepoint>26 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change from baseline in chronic kidney disease (CKD) stage</outcome>
      <timepoint>26 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change from baseline in hematologic parameters (platelets, LDH, hemoglobin)</outcome>
      <timepoint>26 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Increase in hemoglobin = 20g/L from baseline</outcome>
      <timepoint>26 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change from baseline in quality of life, as measured by the EQ-5D-3L (all patients)</outcome>
      <timepoint>26 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change from baseline in quality of life, as measured by the FACIT Fatigue Version 4 questionnaire (patients = 18 years of age)</outcome>
      <timepoint>26 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change from baseline in quality of life, as measured by the Pediatric FACIT Fatigue questionnaire (patients 12 to &lt; 18 years of age)</outcome>
      <timepoint>26 weeks</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1. Male or female = 12 years of age and weighing = 40 kg at the time of consent.

          2. Evidence of thrombotic microangiopathy (TMA), including low platelet count, hemolysis
             (breaking of red blood cells inside of blood vessels), and decreased kidney function

          3. Documented meningococcal vaccination not more than 3 years prior to, or at the time
             of, initiating study drug. Patients who receive a meningococcal vaccine less than 2
             weeks before initiating ALXN1210 treatment must receive treatment with appropriate
             prophylactic antibiotics until 2 weeks after vaccination. Patients who have not been
             vaccinated prior to initiating ALXN1210 treatment should receive prophylactic
             antibiotics prior to and for at least 2 weeks after meningococcal vaccination.
             Patients &lt; 18 years of age must have been vaccinated against Haemophilus influenzae
             type b (Hib) and Streptococcus pneumoniae according to national and local vaccination
             schedule guidelines.

          4. Female patients of childbearing potential must use highly effective contraception
             starting at screening and continuing until at least 8 months after the last dose of
             ALXN1210</inclusivecriteria>
    <inclusiveminage>12</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1. ADAMTS13 deficiency (Activity &lt; 5%)

          2. Shiga toxin-related hemolytic uremic syndrome (STEC-HUS)

          3. Positive direct Coombs test

          4. Pregnancy or breastfeeding

          5. Identified drug exposure- related hemolytic uremic syndrome (HUS)

          6. Bone marrow transplant (BMT)/hematopoietic stem cell transplant (HSCT) within last 6
             months prior to start of Screening

          7. HUS related to known genetic defects of cobalamin C metabolism

          8. Systemic sclerosis (scleroderma), systemic lupus erythematosus (SLE), or
             antiphospholipid antibody positivity or syndrome

          9. Chronic dialysis (defined as dialysis on a regular basis as renal replacement therapy
             for ESKD)</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>1/11/2016</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>55</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>1/12/2019</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <hospital>Clinical Trial Site - Adelaide</hospital>
    <hospital>Clinical Trial Site - Geelong</hospital>
    <hospital>Clinical Trial Site - Parkville</hospital>
    <postcode> - Adelaide</postcode>
    <postcode> - Geelong</postcode>
    <postcode> - Parkville</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Indiana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Ohio</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Austria</country>
      <state>Vienna</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Bordeaux</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Clermont-Ferrand</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Paris</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Aachen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Essen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Saitama</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Tokyo</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Gyeonggi-do</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Seoul</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Barcelona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Madrid</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Taiwan</country>
      <state>Taipei</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Cardiff</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Glasgow</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>London</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Alexion Pharmaceuticals</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of the study is to assess the efficacy of ALXN1210 to control disease activity in
      adolescent and adult patients with aHUS who have not previously used a complement inhibitor.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02949128</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name>Alexion Pharmaceuticals, Email for a Complete Site List</name>
      <address />
      <phone />
      <fax />
      <email>clinicaltrials@alexion.com</email>
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>